Invivyd Inc (NASDAQ: IVVD) shares are trading higher after the company released initial results from the ongoing CANOPY Phase 3 pivotal clinical trial of VYD222, a broadly neutralizing, half-life extended monoclonal antibody candidate, for the prevention of
Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic castration-res
Structure Therapeutics Inc (NASDAQ: GPCR) shares are trading lower after the company provided a comprehensive development program update for its highly selective oral GLP-1
Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), announced that it has been selected by Ultragenyx (NASDAQ:RARE) to
Sysco Corporation (NYSE:SYY), and iFoodDS announced a proof-of-concept project to explore solutions that enable Sysco and its diverse supplier base to capture, store, and share data required by the U.S. Food and Drug
- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels -
- A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion Achieved Marked Tumor Shrinkage after One Cycle